published meta-analysis   sensitivity analysis   studies

ivermectin in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsOkumuş, 2020 0.58 [0.18; 1.91] 0.58[0.18; 1.91]Okumuş, 202010%60NAnot evaluable clinical improvementdetailed resultsCamprubi, 2020 0.68 [0.12; 3.87] Okumuş, 2020 1.51 [0.54; 4.24] 1.23[0.50; 2.98]Camprubi, 2020, Okumuş, 202020%86moderatenot evaluable clinical improvement (7-day)detailed resultsCamprubi, 2020 0.68 [0.12; 3.87] 0.68[0.12; 3.87]Camprubi, 202010%26NAnot evaluable viral clearance detailed resultsCamprubi, 2020 0.52 [0.10; 2.58] 0.52[0.10; 2.58]Camprubi, 202010%26NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-05-24 00:58 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 684,886 - roots T: 290